Abivax shares surged 29.5% to €107.9 following the firm's late-week disclosure of positive Phase 3 data for obefazimod in patients with refractory ulcerative colitis. The announcement, filed Sunday evening via an SEC Form 6-K and distributed through a GlobeNewswire press release, provided results from Part 2 of the ABTECT maintenance trial and an expanded integrated safety review that together reshaped investor sentiment.
Part 2 of the ABTECT maintenance study is a supplemental cohort that enrolled two specific groups: patients who did not respond to initial induction therapy and patients who relapsed during a prior re-randomized maintenance phase. The readout focused on outcomes at Week 44 for subjects treated with a continuous 50 mg dose of obefazimod and for relapsing patients who were escalated to that same 50 mg dose.
Among those who did not respond to induction therapy, 37.2% achieved clinical remission at Week 44, while 34.5% reached endoscopic remission on continued 50 mg obefazimod. For patients who had relapsed and were escalated to 50 mg, clinical remission rates were approximately 45% across both of the relapsing sub-groups reported.
Equally material to market reaction was the safety information included in the filing. Abivax presented an expanded integrated safety database that spans its Phase 2 and Phase 3 programs. Within that dataset, exposure-adjusted malignancy incidence rates were reported to fall within published background ranges for ulcerative colitis, directly addressing a cancer-signal concern that had weighed heavily on the stock. That safety anxiety had previously precipitated a roughly 40% single-session collapse in the share price in early June.
Abivax also reconfirmed its regulatory roadmap, stating it remains on track to submit a New Drug Application to the U.S. Food and Drug Administration in the fourth quarter of 2026. The combination of efficacy in a more refractory patient population, a safety profile aligned with background incidence ranges, and an uninterrupted path toward an NDA created a clear impetus for investors to reassess valuation.
Analyst positioning ahead of the readout provided additional support to the recovery in the stock. Several firms had maintained Buy or Overweight ratings in the lead-up to the ABTECT Part 2 results, including Citizens, Piper Sandler, Barclays, Guggenheim, Truist, and Morgan Stanley, with price targets that the company notes are well above the then-current trading levels.
The broader market environment was also constructive. The pan-European STOXX 600 was on pace for its strongest quarterly gain since October 2020, and France's CAC 40 - Abivax's home index - traded modestly higher on the day of the release. That backdrop helped amplify the impact of the clinical and safety news.
Together, the data and safety reassurances triggered one of the sharpest single-session recoveries for the stock in recent months, pushing Abivax back toward the upper portion of its 52-week range. Investors responded to the combination of robust efficacy signals in a challenging patient cohort, a materially improved safety narrative, and a maintained regulatory timeline toward a late-2026 NDA as reasons to re-price the shares.
Summary
Positive Phase 3 results from Part 2 of the ABTECT maintenance trial and an expanded safety database showing malignancy rates within ulcerative colitis background ranges prompted a near-30% jump in Abivax shares. The company reaffirmed its plan to file an NDA in Q4 2026.
Key points
- Clinical impact - Obefazimod produced 37.2% clinical remission and 34.5% endoscopic remission at Week 44 among induction non-responders on 50 mg, while relapsing patients escalated to 50 mg showed clinical remission rates of about 45%.
- Safety reassessment - An integrated Phase 2/Phase 3 safety review found exposure-adjusted malignancy incidence rates that fall within published ulcerative colitis background ranges, countering earlier cancer-signal concerns that had pressured the stock.
- Market context - Analyst buy/overweight recommendations and a strong European equity backdrop, including a robust quarter for the STOXX 600 and modest gains in the CAC 40, supported the stock's rebound.
Risks and uncertainties
- Regulatory timing - The company remains on track for an NDA submission in Q4 2026, but the filing and subsequent review process will determine regulatory outcomes that are not addressed by the current readout.
- Residual safety scrutiny - While the integrated safety data reported malignancy rates within background ranges, prior safety concerns had previously driven a sharp share-price decline; continued monitoring and future data will influence risk perception.
- Analyst and market sensitivity - The stock's recent rebound was supported by pre-existing analyst ratings; changes in analyst views or macro market conditions could affect valuation and share performance.